Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study*-Reference-Cited by-同舟云学术

Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study*

Published:2021-06-15 Issue:4 Volume:185 Page:745-755
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Murrell D.F.¹^ORCID,Patsatsi A.²,Stavropoulos P.³,Baum S.⁴,Zeeli T.⁵,Kern J.S.⁶,Roussaki‐Schulze A.‐V.⁷,Sinclair R.⁸,Bassukas I.D.⁹,Thomas D.¹⁰,Neale A.¹⁰,Arora P.¹⁰,Caux F.¹¹,Werth V.P.¹²^ORCID,Gourlay S.G.¹⁰,Joly P.¹³,

Affiliation:

1. Department of Dermatology St George Hospital University of New South Wales Faculty of Medicine Sydney NSW Australia

2. 2nd Dermatology Department Aristotle University Faculty of Medicine Papageorgiou General Hospital Thessaloniki Greece

3. 1st Department of Dermatology National and Kapodistrian University School of Medicine Athens Greece

4. Department of Dermatology Sheba Medical Center, Ramat Gan, Israel and Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

5. Department of Dermatology Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

6. Dermatology Department The Royal Melbourne Hospital Faculty of Medicine, Dentistry and Health Sciences the University of Melbourne Melbourne VIC Australia

7. Department of Dermatology University General Hospital of Larissa Larissa Greece

8. University of Melbourne and Sinclair Dermatology Melbourne VIC Australia

9. Department of Skin and Venereal Diseases School of Health Sciences University of Ioannina Ioannina Greece

10. Principia Biopharma Inc., a Sanofi Company South San Francisco CA USA

11. Department of Dermatology Groupe Hospitalier Paris Seine‐Saint‐Denis AP‐HP Bobigny France

12. University of Pennsylvania and Corporal Michael J. Crescenz VAMC Philadelphia PA USA

13. Department of Dermatology Rouen University Hospital Centre de Référence des Maladies Bulleuses Autoimmunes, and INSERM U1234 Normandie University Rouen France

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.20431

Reference29 articles.

1. Pemphigus: Current and Future Therapeutic Strategies

2. Prevalence Estimates for Pemphigus in the United States

3. Diagnosis and management of pemphigus: Recommendations of an international panel of experts

4. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bruton Tyrosine Kinase Inhibition Decreases Inflammation and Differentially Impacts Phagocytosis and Cellular Metabolism in Mouse- and Human-derived Myeloid Cells;ImmunoHorizons;2024-09-01

2. Updates on the Management of Autoimmune Bullous Diseases;Indian Dermatology Online Journal;2024-08-30

3. Targeting Bruton’s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments;Advances in Rheumatology;2024-08-21

4. The potential of Bruton’s tyrosine kinase (BTK) inhibitors in the pharmacotherapeutic management of immune and dermatological disease;Expert Opinion on Pharmacotherapy;2024-08-12

5. Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study;Journal of Investigative Dermatology;2024-08